China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

SSZSE:300294
13.25
CNY
-0.04
(-0.30%)
-0.34EPS
7.53BMarket Cap
Mar 22Next Earn

Total Valuation

CNY

As of September 30, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 7.53B, placing it among publicly traded companies globally. Its enterprise value stands at 4.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.53B
Enterprise Value4.82B

Important Dates

China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A's next confirmed earnings release is scheduled for March 22, 2027.

Earnings Date3/22/2027

Share Statistics

As of September 30, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A has 504.25M shares outstanding.

Shares Outstanding504.25M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 5.26, and the price-to-book ratio stands at 1.01.

PS Ratio5.26
PB Ratio1.01
P/TBV Ratio1.20

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 3.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.82B versus a market cap of 7.53B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.37

Financial Position

As of September 30, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 7.61, meaning it holds 7.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.00, indicating moderate leverage, while an interest coverage ratio of -93.12 demonstrates limited ability to service its debt obligations.

Current Ratio7.61
Quick Ratio4.21
Debt / Equity1.00
Debt / EBITDA-0.34
Interest Coverage-93.12

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 735,530.99 in revenue per employee across its workforce of 1,947.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee735,530.99
Employee Count1,947.00

Taxes

CNY

Over the twelve months ended September 30, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A recorded an income tax benefit of -66.84M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -236.66M and -167.93M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-66.84M

Stock Price Statistics

CNY

As of the close on November 17, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 47.04% over the past 52 weeks. The 50-day moving average sits at 14.26, while the 200-day moving average is 16.95.

52-Week Price Change-47.04%
50-Day Moving Average14.26
200-Day Moving Average16.95

Income Statement

CNY

Over the twelve months ended September 30, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A generated 1.43B in revenue and converted that into -167.93M in net income, yielding earnings per share of -0.34. EBITDA reached -221.12M, while operating income came in at 72.79M.

Revenue1.43B
Gross Profit592.39M
Operating Income72.79M
Pretax Income-236.66M
Net Income-167.93M
EBITDA-221.12M
EBIT-221.12M
Earnings Per Share (EPS)-0.34

Balance Sheet

CNY

As of September 30, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A holds 2.79B in cash and equivalents against 74.16M in total debt, resulting in a net debt position of -691.32M. Total book value stands at 7.45B, with working capital of 4.37B providing operational flexibility.

Cash & Cash Equivalents2.79B
Total Debt74.16M
Net Debt-691.32M
Equity (Book Value)7.45B
Book Value Per Share14.77
Working Capital4.37B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-471.50M

Margins

Over the twelve months ended September 30, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A posted a gross margin of 41.37, reflecting its pricing power and cost economics. The operating margin of 5.08 and net profit margin of -11.73 provide insight into operational efficiency.

Gross Margin41.37
Operating Margin5.08
Pretax Margin-16.53
Profit Margin-11.73
EBITDA Margin-15.44

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A paid dividends of 0.07 per share. The dividend payout ratio of -21.64 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.10, meaning China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.07
Payout Ratio-21.64
Shareholder Yield-0.10

Stock Splits

China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on May 26, 2017 with a 2:3 split ratio.

Last Split Date5/26/2017
Split Ratio2:3

Scores

As of September 30, 2026, China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 7.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.14